Overview
The purpose of this study is to evaluate association between ozanimod exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.
Eligibility
Inclusion Criteria:
- Currently or recently pregnant
- Diagnosis of UC
- Resident of country where ozanimod is prescribed for the treatment of UC
Exclusion Criteria:
- Exposure to other S1P therapies at any time during pregnancy
Other protocol-defined eligibility criteria apply.


